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Abstract 
Type II Diabetes Mellitus is an endocrine disorder that affects people of all ages. Type II 
Diabetes was once considered adult-onset diabetes, as it was nearly exclusively 
diagnosed in adults. Over the last three decades, the number of children diagnosed with 
Type II Diabetes has greatly increased. This rapid increase in childhood Type II Diabetes 
has prompted researchers to investigate why the epidemic exists and what its life-long 
ramifications may be for those diagnosed. Childhood Type II Diabetes is a heterogeneous 
disorder, meaning it is caused by both genetic and environmental factors. The incidence 
of childhood Type II Diabetes can only be reduced by an alteration in environmental 
factors, which are called modifiable risk factors. These include obesity, exercise, diet, 
and breastfeeding in infancy. Due to the chronic nature of Type II Diabetes, individuals 
with the disorder are at significant risk for developing additional medical conditions, or 
co-morbidities. These include cardiac diseases, renal failure, and vision impairment. Due 
to the early onset of childhood Type II Diabetes, these co-morbidities are often 
pronounced and debilitating once the child has reached middle adulthood. To reduce 
lifelong complications, screening for Type II Diabetes should be initiated early in at-risk 
children.  
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Childhood Type II Diabetes: Risks and Complications 
 Diabetes Mellitus is considered an epidemic in the United States. Over 29.1 
million Americans, or 9.3% of the population, have been diagnosed with the disease as of 
2012 (National Diabetes Statistics Report, 2014). While the incidence of diabetes is 
quickly growing, the gravity of the disease’s risks and complications are often not 
realized. Yet, according the American Diabetes Association (ADA), diabetes currently 
ranks as the 7th leading cause of death in the United States (National Diabetes Statistics 
Report, 2014). At this time, diabetes is considered a treatable yet incurable disease, 
magnifying the complications associated with its diagnosis (Taylor, 2013). Diabetes is a 
metabolic disease characterized by the body’s inability to properly utilize glucose. There 
are two distinct categories of diabetes: Type I and Type II. Type II Diabetes Mellitus 
(DMII) is similar to Type I Diabetes (DMI) in many ways. However, recognizing the 
differences between the two disease processes is vital to understanding the risks, treating 
the disease, and preventing complications. Both DMI and DMII can be diagnosed in 
childhood. The diagnosis of DMII in childhood is predicated by several risk factors and 
wrought with lifelong complications.  
Pathophysiology of Childhood DMII 
Diabetes is a metabolic disease in which a person has abnormally high blood 
glucose levels. Under normal physiological conditions, blood glucose levels will be 
controlled between 70 and 125 mg/dL, despite wide fluctuations in the supply of glucose 
and demand for insulin. A high blood glucose level is referred to as hyperglycemia. 
Hyperglycemia is the result of impaired insulin release due to a dysfunction of the 
pancreatic beta cells and diminished insulin efficacy due to insulin resistance by the 
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body’s tissues (Ozougwu, Obimba, Belonwu, & Unakalamba, 2013). Insulin, a peptide 
hormone produced by the pancreas, is the body’s means of controlling blood sugar levels 
by withholding and releasing glucose as it is needed for appropriate body function. The 
primary difference between DMI and DMII is how the body produces and utilizes insulin. 
Type I Diabetes leaves individuals dependent on insulin supplements due to the pancreas’ 
inability to produce insulin. Individuals with DMII may still produce insulin, but their 
bodies are unable to utilize it effectively (Copeland et al., 2013). The body’s inability to 
effectively utilize insulin is called insulin resistance. Insulin resistance in DMII is 
generally due to one of three issues. Insulin resistance may be the result of a signaling 
defect. In such a case, the pancreas is not signaled to release insulin when the body needs 
it, resulting in inadequate insulin release and hyperglycemia. Insulin resistance may be 
due to a glucose transporter defect. This means that the pancreas is producing enough 
insulin, but it is not being transported effectively to control blood glucose. Insulin 
resistance may be caused by lipotoxicity (Taylor, 2013). Lipotoxicity is an accumulation 
of toxic lipid metabolites in the body’s tissues, including the liver and arteries. This 
buildup acts as a barrier and prevents proper insulin use by the affected tissues. 
Lipotoxicity, which is essentially excess tissue fat, is driven by obesity (DeFronzo, 2010).  
Depending on the type and severity of insulin resistance associated with DMII, 
the treatment varies. Some individuals may be able to initially manage their DMII with 
diet and lifestyle changes alone. If this is not enough, oral medications will be used to 
promote insulin utilization. However, if insulin production is impaired or deficient, the 
individual will require insulin therapy to manage his or her DMII and resulting 
hyperglycemia.  
CHILDHOOD TYPE II DIABETES  6 
Prevalence of Childhood DMII 
 Type II Diabetes was long considered a disease of adulthood until the 1980s when 
children and adolescents were increasingly diagnosed with the endocrine disease. In 
2001, DMII accounted for three percent of diabetes diagnoses in children, while DMI 
accounted for 97%. As of 2011, DMII accounted for 45% of the childhood diabetes 
diagnoses (D’Adamo & Caprio, 2011). Thus, in only one decade, the prevalence of DMII 
in children increased from three percent to 45% of diabetic cases. The prevalence of 
DMII is 1.7 per 1000 children and adolescents in the United States (Center for Disease 
Control and Prevention [CDC], 2013).  The CDC (2013) suggested that the rate of 
childhood DMII could increase four times over the next 40 years. The average age of 
onset of childhood DMII coincides with the physiological insulin resistance of puberty. 
While children are most commonly diagnosed between the ages of 11-14, children as 
young as 5 years old are increasingly being diagnosed with DMII (D’Adamo & Caprio, 
2011). Although childhood DMII was once a rare diagnosis, it has become an epidemic in 
the United States (CDC, 2013).  
Risk Factors of Childhood DMII 
 The etiology of DMII is heterogenous in that both genetics and environment 
contribute to the disease (“Type 2 Diabetes”, 2010). Genetic causes are often called non-
modifiable risk factors. These factors are those that cannot be modified or altered; thus, 
they are permanent and irreversible risk factors for developing DMII. Environmental 
factors are often called modifiable risk factors. These factors, such as diet and lifestyle, 
can be modified to prevent the development of DMII.  
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Non-modifiable Risk Factors 
 Non-modifiable risk factors cannot be prevented or reversed. There are three 
primary non-modifiable risk factors that have been identified in the etiology of DMII: 
intrauterine exposure, family history, and ethnicity (Kommoju & Reddy, 2011). While 
these factors all contribute to the development of DMII, they do not necessarily explain 
the current epidemic of childhood DMII.  
Intrauterine exposure. One factor strongly associated with the diagnosis of 
DMII in children is their intrauterine exposure to maternal diabetes. Maternal diabetes 
diagnoses can include DMI, DMII, and gestational diabetes. It is proposed that neonates’ 
intrauterine exposure to diabetes is largely the result of maternal hyperglycemia and an 
unstable insulin-glucose balance throughout gestation. However, studies have shown that 
fetal intrauterine exposure to diabetes is still a risk factor, despite excellent maternal 
control of blood glucose levels throughout the pregnancy. Intrauterine exposure to 
maternal diabetes predisposes children to developing DMII in several respects, including 
hyperglycemia, macrosomia, and impaired endocrine development.  
Hyperglycemia. Children of mothers with diabetes are exposed to a 
hyperglycemic intrauterine environment throughout the pregnancy. The maternal 
hyperglycemia leads to increased glucose transfer to the fetus via the umbilical cord. This 
forces the fetus to increase insulin secretion to prevent fetal hyperglycemia. When these 
infants are born, their bodies continue to expect high levels of blood glucose. If the high 
levels of blood glucose are not achieved through the infant’s nutrients, the infant’s 
pancreas will naturally produce less insulin to maintain the expected hyperglycemic state. 
Additionally, the elevated insulin production required by the infant in-utero leads to 
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inefficient insulin use and premature insulin resistance in childhood. This is a precursor 
for the development of DMII (Ruchat, Hivert, & Bouchard, 2013). Essentially, 
intrauterine exposure to maternal hyperglycemia results in impaired endocrine control in 
the infant. Depending on the severity and longevity of the hyperglycemic exposure, the 
infant may experience lifelong metabolic complications as a result. In addition to 
maternal hyperglycemia, the infant’s birth weight is important.  
Macrosomia. Macrosomia is the term to describe an infant with an excessive birth 
weight. An infant’s weight at birth is influenced by the mother’s metabolic and endocrine 
function. Even diabetic mothers with excellent glucose control throughout pregnancy 
may give birth to macrosomic infants. It is important to note that while the infants are 
macrosomic, it is specifically an excess of fat mass rather than lean body mass. Research 
indicates that an increase in infants’ fat mass persists even when their birth weight is 
appropriate for gestational age. This indicates that maternal diabetes causes increased 
buildup of fat tissue in neonates, even when blood glucose is controlled. Ultimately, the 
intrauterine metabolic environment affects the infant’s adipose growth, predisposing the 
child to endocrine dysfunction (Catalano & Hauguel-De Mouzon, 2011).  
Impaired endocrine development. Exposure to maternal diabetes can also lead to 
impaired endocrine development in neonates. When infants are exposed to intrauterine 
hyperglycemia, they are forced to produce excess insulin, this is known as 
hyperinsulinism. When hyperinsulinism occurs during the first trimester, which is a 
critical period of brain development, it can lead to impaired development and permanent 
maladaptation of the hypothalamic center that regulates endocrine function. This 
maladaptation results in lifelong endocrine complications for the infant, including early 
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development of DMII. Several studies have followed the endocrine development of 
children who were exposed to intrauterine hyperglycemia, revealing the correlation 
between the exposure and lifelong endocrine maladaptation (Ruchat et al., 2013). The 
growth patterns and risk of DMII in children exposed to diabetes in-utero are influenced 
by unique gene-environment interactions. Consequently, children exposed to DMII and 
hyperglycemia while in-utero have a higher risk for obesity, insulin resistance, and the 
development of DMII in childhood (Mendelson et al., 2011).  
Family History of DMII. Children are at a higher risk of developing DMII if 
they have an immediate family member also diagnosed with diabetes, whether DMI or 
DMII. There appears to be a strong connection between family history and childhood 
diagnosis of DMII. The risk of developing DMII is 40% for individuals who have one 
parent with the disease and 70% if both parents are affected (Ahlqvist, Ahluwalia, & 
Groop, 2011). This is due, in part, to the genetic prevalence of obesity and its role in the 
diagnosis of DMII. However, several studies and genome mapping suggests that there is 
a genetic factor related to the body’s glucose control and ability to effectively utilize 
insulin (Santoro et al., 2013). Current research indicates a strong connection between the 
TCF7L2 and MTNR1B genes and DMII (Ahlqvist et al., 2011). It is important for 
children of parents with diabetes to be screened starting in elementary school to ensure 
early diagnosis of DMII.  
Excess glucose production. Glucose production is affected by genetics. Genetic 
mapping allows one to identify specific genes that increase susceptibility to a disease or 
influence a physiological characteristic. Several genes have been identified as influential 
in the development of DMII. Transcription factor 7-like 2 (TCF7L2) is a protein that has 
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been identified as a genetic factor leading to increased rate of hepatic glucose production. 
Several studies have confirmed the association between DMII and several single-
nucleotide polymorphisms (SNPs) in the TCF7L2 gene (Ahlqvist et al., 2011). These 
studies were performed in several ethnic groups, all confirming the association between 
the TCF7L2 gene, excess hepatic glucose production, and the development of DMII. 
Decreased insulin production. Insulin production is also affected by genetics. 
Another important gene involved in the development of DMII is melatonin receptor 1B 
(MTNR1B). Melatonin receptor 1B is associated with elevated fasting blood glucose and 
the development of DMII due to its influence in the production of insulin. Melatonin, 
often referred to as the sleep hormone, works primarily to adjust the body’s biological 
clock. There are melatonin receptors located in the pancreas that contribute to the 
nocturnal lowering of insulin levels to maintain fasting blood glucose throughout the 
night. However, a mutation in the MTNR1B gene is associated with altered melatonin 
signaling at the pancreas. Initially, this mutation causes mild overproduction of insulin, 
which often goes unnoticed. However, genetic studies suggest that over time the pancreas 
will become maladapted to the MTNR1B mutation, resulting in diminished insulin 
production, hyperglycemia, and ultimately the development of DMII (Ahlqvist et al., 
2011). Research is ongoing to determine the genetic factors associated with DMII.  
Ethnicity. Another genetic factor that predisposes children to DMII is ethnicity. 
Certain ethnicities, specifically African Americans, Native Americans, Asian Americans, 
and Hispanics have higher rates of childhood DMII (Agency for Healthcare Research and 
Quality, 2013). Compared to these ethnicities, Caucasian children have a lower 
prevalence of DMII and are less likely to be diagnosed with the disease. It has been 
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suggested that obesity, rather than ethnicity, is the cause of higher incidence of DMII in 
certain ethnic groups. However, recent ethnicity studies have shown that, regardless of 
weight, ethnicity is a factor in the development of DMII. In 2010, the National Institute 
of Health (NIH) conducted a study that examined the prevalence of DMII in children of 
five different ethnicities. The five ethnicities included in the study are Non-Hispanic 
whites, Hispanics, African Americans, Navajo Indians, and Asian Americans. Several 
factors including blood pressure, cholesterol, and obesity were studied. The study ranked 
the prevalence (per 1000) of DMII in children from highest to lowest: Navajo Indians 
(1.45), African Americans (1.06), Asian Americans (0.52), Hispanics (0.46), and Non-
Hispanic whites (0.18). The study also ranked the percentage of children diagnosed with 
DMII who are also obese from highest to lowest: African Americans (94), Non-Hispanic 
whites (92), Asian Americans (90), Navajo Indians (85), and Hispanics (83). It is 
interesting to note that while Navajo Indians have the highest prevalence of childhood 
DMII, they also claim the second lowest obesity rate. In the same respect, Non-Hispanic 
whites have the lowest prevalence of DMII by a significant margin, yet claim a close 
second in obesity rates (Brown & Rother, 2010). This study does not deny the influence 
of obesity in the diagnosis of childhood DMII, but it illustrates the relevance of ethnicity 
in the development of the endocrine disease. As such, children of African American, 
Native American, and Hispanic ethnicity are considered high-risk for developing DMII 
(Bobo, Shantz, Kaufman, & Kollipara, 2009).  
Modifiable Risk Factors 
Modifiable risk factors are those that can be avoided or reversed in children to 
prevent the onset of DMII. Modifiable risk factors include obesity, exercise, diet, and 
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breastfeeding in infancy.  The majority of modifiable risk factors, however, are largely 
out of the child’s control, this includes lifestyle. Factors such as diet and breastfeeding in 
infancy are two factors that are controlled by the parents rather than the child. These pose 
a unique risk to childhood DMII and necessitate early intervention.  
Obesity. Obesity is the most significant risk factor for developing childhood 
DMII. Children who are overweight or obese are at a significantly greater risk for 
developing DMII than children of healthy weight. In the US, overweight and obese are 
defined as the 85th and 95th percentiles for weight, respectively. There is an increase in 
the prevalence of childhood DMII from 2.4% for children of normal weight to 14.2% for 
children who are obese. Because body mass index (BMI) changes so rapidly in children, 
it is generally not considered reliable in defining overweight and obese. A 2011 report 
indicates that 15-17% of children, ages 6-17, are considered obese in the US. The 
increasing rates of childhood DMII are closely paralleled with increasing rates of 
childhood obesity (Rabbitt & Coyne, 2012).  
The risk for DMII is associated with obesity’s affect on insulin sensitivity and 
glucose utilization. Children who are overweight or obese experience impaired glucose 
tolerance (IGT), characterized by significant peripheral insulin resistance and subsequent 
beta-cell failure. In normal weight children, a balance between the pancreas’ beta-cell 
insulin secretion and insulin sensitivity of the peripheral tissues maintains glucose 
metabolism. The peripheral tissues include muscle, liver, and adipose tissue. In 
overweight or obese children, impaired beta-cell function caused by excess visceral fat 
and decreased insulin sensitivity by the peripheral tissues due to peripheral fat are the two 
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primary components in the development of DMII. Insulin resistance is the major link 
between obesity and DMII (Yaturu, 2011).  
Insulin resistance can be caused by numerous factors, however an excess of free 
fatty acids (FFA) plays a leading role. Visceral fat causes an increase in the release of 
FFA, as a result of accelerated lipolytic activity. Current research suggests that an 
oversupply of lipid to skeletal muscle, as is found in overweight and obesity, contributes 
to diminished insulin sensitivity. Increased FFA also results in the development of 
triglyceride buildup in both muscle and the liver, inhibiting the efficacy of insulin.  The 
FFA buildup causes insulin resistance as the result of several physiologic changes. First, 
FFAs inhibit insulin-stimulated glucose uptake at the level of glucose transport. This 
means that while the body is producing adequate insulin, the FFAs prevent it from being 
used to effectively maintain blood glucose levels. Second, FFAs impede insulin-
stimulated glycogen synthesis. In a normal physiologic process, insulin will assist in the 
conversion of glucose to glycogen for storage purposes. However, in the presence of 
excess FFAs, insulin cannot efficiently or effectively synthesize the blood glucose into 
glycogen. In addition to provoking impaired insulin sensitivity, excess FFAs also 
contribute to overstimulation and increased production of hepatic glucose. This is due to 
suppression of glycogenolysis and gluconogenesis. Without these factors, hepatic glucose 
production becomes unchecked. Elevated FFAs play a direct role in the overproduction 
of hepatic glucose. Consequently, overweight and obese children have a significantly 
greater likelihood of developing DMII. It is also important to note that children have a 
decreased tolerance to unstable blood glucose levels as compared to adults. This means 
that when children experience FFA induced hyperglycemia and insulin sensitivity, it 
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quickly progresses to DMII (Yaturu, 2011). There is a narrow window for intervention 
once FFAs have taken their toll, indicating the need for early screening.  
Physical inactivity. Physical inactivity is an important risk factor and one of the 
most easily modified factors in the prevention of childhood DMII.  The effect of physical 
activity on insulin resistance and susceptibility to DMII in children is immense. Physical 
activity is proven to improve body composition, lower the resting heart rate, and lower 
blood pressure in children. High-risk DMII children experience additional benefits of 
exercise, including improved insulin sensitivity and balanced glucose uptake in the 
periphery. As a result, adequate physical activity has the potential to drastically reduce 
insulin resistance and the incidence of childhood DMII (Tompkins, Soros, Sothern, & 
Vargas, 2009). Research conducted over the last decade has demonstrated a positive 
association between physical activity and insulin utilization, showing that increased 
activity leads to balanced fasting glucose levels and improved insulin sensitivity.  
There are two key ways that physical activity improves insulin sensitivity, thus 
lowering the risk of developing DMII. First, physical activity improves insulin sensitivity 
by increasing glucose transport to muscle cells and encouraging the production of muscle 
glycogen to maintain blood glucose levels. Second, physical activity has long-term 
implications for insulin sensitivity and blood glucose maintenance. By increasing the fat-
free muscle mass, exercise increases the volume of muscle into which blood glucose can 
be transported. The expansion of muscle volume lowers the demand for insulin while 
simultaneously promoting better utilization of blood glucose (Lumb, 2014). Dr. Connie 
Tompkins and associates (2009) reported a study on the effects of aerobic exercise on 
insulin sensitivity in overweight and obese 9-15 year olds. The study found that, after 12 
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weeks of aerobic training, insulin sensitivity increased without any significant changes in 
body weight or fat mass. Furthermore, the study discovered that lower limb fat-free mass 
increased by an average of 6.2%. This change in fat-free mass, as addressed earlier, is 
significantly associated with improved insulin sensitivity and blood glucose control. A 
reduction in peripheral fat allows for better utilization of insulin in the peripheral tissues.  
It is important to note that, in most cases, obesity and physical inactivity are 
coexisting factors. The two factors tend to work in a cyclic pattern, since obesity impairs 
physical mobility and inactivity promotes obesity. As such, the two factors are often 
addressed simultaneously by encouraging physical activity in early childhood and 
throughout development. An important aspect of exercise is the different types of 
physical activity. The U.S. Government Physical Activity Guidelines for American 
Children and Adolescents includes both aerobic and resistance, or strength, training as 
elements to prevent the development of DMII. According to these guidelines, the best 
option for children is combination exercise, which includes both aerobic and weight 
lifting exercises (“Youth Physical Activity”, 2014). Aerobic activity recommendations 
include swimming, playing tag, and organized sports such as soccer. Strength training 
recommendations include climbing trees, martial arts, and swinging on monkey bars. The 
recommendation for high-risk children is 40-60 minutes/day of moderate to vigorous 
aerobic/resistance combination exercise, five days a week. After four consecutive months 
of this regimen, insulin sensitivity will improve and the child’s risk of developing DMII 
will decrease (Tompkins et al., 2009). 
Diet. Diet plays a significant role in the development of childhood DMII. The 
foods that children eat directly impact the body’s ability to utilize insulin effectively. 
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Because insulin is necessary for proper glucose storage, transfer, and use, the relationship 
between diet and DMII is critical (Dabelea & Harrod, 2013). Extensive research been 
conducted in the last five years to better understand the dynamic between diet and 
childhood DMII. The ADA reported a study from the UK, led by Dr. Angela Donin 
(2014), which looked at several dietary factors in relation to childhood DMII. The study 
examined the correlation between total energy intake, energy density, dietary nutrient 
intakes, and risk markers for DMII in a large, cross-sectional, multiethnic population of 
9–10-year-old children. The study procured a structured 24-hour diet recall from the 
2,569 participants. The energy and nutrient intakes were calculated using the Medical 
Research Council Human Nutrient Research Center’s standards for childhood nutrition 
needs. By using an estimate of basal metabolic rate (BMR), the study was able to identify 
several dietary risk markers for DMII.  
For many years, it was believed that the greatest dietary risk factor associated 
with DMII was fat intake. However, current research disproves this theory (Donin et al., 
2014). In fact, of all the dietary factors identified in the ADA study, including energy 
intake, energy density, glycemic markers, and fat mass index, there was only a positive 
association between total energy intake and insulin resistance. Total energy intake is 
essentially caloric intake. Other factors, such as energy density or macronutrients, 
showed little to no association with insulin resistance and the development of DMII in 
childhood. This means that the total caloric intake is a more significant risk marker for 
DMII than specific nutrient intake. The study further investigates dietary intake of the 
participants. While overall caloric, or energy, intake is what is most closely associated 
with DMII, the balance of carbohydrate and protein intake is also influential. 
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Carbohydrates, specifically simple carbohydrates, such as donuts, bread, and sugary 
cereal, provide empty calories for children. These foods are high in calories and low in 
nutrients, which causes the child to consume more calories to feel satisfied. Conversely, 
lean protein, such as chicken, beans, and tuna, promote ideal nutrient intake while 
maintaining appropriate caloric intake. Thus, high carbohydrate and low protein diets are 
strongly correlated with insulin resistance and the development of DMII. Excessive 
carbohydrate intake is a primary risk factor in the development of childhood DMII 
(Donin et al., 2014).  
Breastfeeding in infancy. Breastfeeding during infancy plays a critical role in the 
child’s long-term health, specifically in regards to weight and metabolic syndromes. 
Studies indicate that breastfeeding is associated with a 22-24% lower subsequent risk of 
childhood obesity and lower risk for DMII (Gunderson, 2010). The CDC growth charts 
indicate the healthy weight of children from birth through adolescence. Exclusively 
breastfed infants consistently gain weight more rapidly in the first three months of life 
compared to bottle-fed infants. However, after the first three months of life, exclusively 
breastfed infants have lower, healthier weight-for-age compared to bottle-fed infants. 
Several studies have been conducted in the last decade to examine the long-term weight 
and metabolic implications of children who were exclusively breastfed as infants. A 
meta-analysis of 17 studies indicates the duration of breastfeeding is directly associated 
with reduced risk of obesity and DMII in childhood. One of these studies, a population-
based survey of over 15,000 American children between the ages of nine and 14, found 
that the children who were breastfed for longer than seven months were less likely to be 
obese or experience subsequent metabolic disorders (Bartz & Freemark, 2011).  
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While much of the current data focuses on obesity and metabolic disorders in 
general, several studies have been done specifically to find the association between 
breastfeeding and childhood DMII. A reverse study, which identified obese teens with 
DMII and normal weight teens without DMII, found that the teens with DMII were 40% 
less likely to have been breastfed in infancy compared to the teens that did not have 
DMII. Research continues to determine the precise mechanism of defense against DMII 
provided by breastfeeding, as the association is not entirely clear. However, current 
research suggests that breastfed infants are less likely to be overfed since the 
physiological association between the infant’s needs and mother’s milk production is 
somewhat synchronized. It is suggested that bottle-fed infants are more likely to be 
overfed because bottle feedings normally occur on a fixed schedule. Consequently, bottle 
fed infants are trained to expect food at fixed intervals, whereas breastfed infants expect 
food when hungry. This expectation then stays with the child throughout childhood and 
adolescence (Bartz & Freemark, 2011). While this risk factor is modifiable, many parents 
often realize too late that breastfeeding is a way to prevent childhood medical disorders 
such as DMII (Shaw, 2007). Thus, early intervention is essential to provide parents with 
accurate information regarding the benefits of breastfeeding and its association with 
decreased obesity and DMII in childhood.  
Long-term Complications of Childhood DMII 
Childhood DMII has tremendous and long-lasting effects. Not only are the 
ramifications seen throughout childhood, as the young patient learns to cope with 
diabetes, but childhood DMII predisposes an individual to additional significant medical 
conditions later in life. Although additional medical conditions may not develop 
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immediately, most individuals will experience complications within 30 years of diagnosis 
(Michel, 2011). This is especially detrimental for children diagnosed with DMII because 
they will experience the complications at a much younger age than will adults diagnosed 
with DMII. If an adult is diagnosed with DMII at the age of 40, he or she will likely 
experience several comorbid medical conditions by the age of 70. If a child is diagnosed 
with DMII at the age of 10, he or she will likely experience several comorbid medical 
conditions by the age of 40. Thus, by middle age, these DMII children will face 
numerous obstacles that their peers will not face for decades, including significant 
cardiac complications, renal failure, and vision impairment. 
Cardiac Complications 
Cardiac complications are the most common and often the most dangerous 
complication associated with DMII. Nearly 70% of diabetes-related deaths are linked 
directly to cardiac complications, with type II diabetics facing a two- to four-fold higher 
death rate due to heart disease compared to non-diabetics. Type II Diabetes adversely 
affects several aspects of cardiac function, including cardiomyocyte metabolism, cardiac 
insulin signaling and calcium control, and the stimulation of vascular and cardiac fibrosis 
(Gardner, Murray, & Wold, 2013).  These abnormalities all contribute to cardiac 
dysfunction in patients with DMII.  
Alterations in several molecular signaling pathways have been identified in the 
development of cardiac complications due to DMII. Research suggests that impaired 
insulin signaling – the result of hyperinsulinism, hyperglycemia, and insulin resistance – 
likely forms the foundation for imbalances in diabetic cardiac complications. Following 
the initial insulin signaling impairment, diabetics experience subsequent changes in 
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coronary and renal blood vessels as a result of impaired nitric oxide regulation and 
decreased vascular permeability. This causes constriction of the coronary and renal blood 
vessels and over-activation of the Renin-Angiotensin-Aldosterone System (RAAS). 
Finally, increased FFAs and poorly regulated lipid signaling results in the buildup of 
FFAs, called atherosclerosis, and lipotoxicity in the heart and blood vessels. The 
progression of diabetic cardiac complications results in fibrotic buildup throughout the 
cardiac system and progressive overworking of the cardiac muscle (Manadavia, Aroor, 
DeMarco, & Sowers, 2013). Individuals with DMII must be closely monitored for levels 
of High-Density Lipoproteins (HDL) cholesterol, Low-Density Lipoproteins (LDL) 
cholesterol, blood pressure, and triglycerides to determine each individual’s 
cardiovascular risk. Children with DMII consistently display lower levels of HDL and 
higher levels of LDL cholesterol, pre-hypertension or hypertension, and elevated 
triglycerides when compared to their non-diabetic counterparts. This is due in part to diet, 
but also to the nature of DMII and its impact on the body and cardiac function. Many 
cardiovascular risks cannot be controlled once DMII has been diagnosed (Rodriguez, 
2006). Common comorbid cardiac diagnoses associated with DMII include hypertension, 
coronary artery disease, hyperlipidemia, and diabetic cardiomyopathy. 
Hypertension. In the US, hypertension occurs in 70% of all individuals with 
DMII. The American Diabetes Association performed a study in 2013 that found that 
34% of children with DMII between the ages of 8-17 also had hypertension (Pyle, 2013). 
Hypertension is the most commonly occurring comorbid disease process associated with 
DMII (Cheung & Li, 2012). This is in part due to the several risk factors the two diseases 
share, including obesity, hyperlipidemia, and atherosclerosis. Hypertension is caused by 
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plaque build-up in the arteries and veins, which is called atherosclerosis. As 
atherosclerosis worsens, the blood vessels become obstructed or blocked, thus less blood 
is transported to the body tissues. Additionally, plaque is made up of a firm shell 
containing soft fat, cholesterol, calcium, fibrous tissue, and other substances in the blood. 
As blood hits the plaque during each heartbeat, the plaque weakens and eventually cracks 
open to expose the soft cholesterol. This newly exposed cholesterol promotes abnormal 
blood clotting, which further impairs necessary blood flow to the body by creating 
additional structural barriers that blood flow must work against (Matfin, 2009). Diagnosis 
of hypertension prior to adulthood presents the individual with additional medical 
complications and comorbid factors. Children who are diagnosed with DMII have a 
significant risk of developing hypertension during their childhood or adolescent years. 
 Coronary Artery Disease. Coronary Artery Disease (CAD), also known as 
coronary heart disease, is the leading cause of mortality among patients with DMII 
(“Cardiovascular Disease”, 2014). Cardiologists Nima Alipour, Nathan Wong, and 
Shaista Malik (2012) suggest that 50% of DMII patients have or will develop CAD 
during their lifetime. Coronary artery disease occurs when the arteries that supply blood 
to the heart, called the coronary arteries, become hard and narrow. As with hypertension, 
this is caused in part by atherosclerosis and plaque buildup along the lining of the vessels. 
Coronary artery disease is particularly dangerous for two reasons. First, the coronary 
arteries are fairly small, which means even minimal atherosclerotic buildup can prevent 
adequate blood flow. Second, the coronary arteries supply blood directly to the cardiac 
muscle. If the heart is not supplied with adequate blood flow via the coronary arteries, the 
entire body is affected. Over time, less blood is able to flow through the coronary arteries 
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to supply the heart with essential blood and oxygen. Diminished blood flow to the heart 
can lead to angina or heart attack. Coronary artery disease also contributes to weakening 
the cardiac muscle and the development of heart failure and arrhythmias (Alipour et al., 
2012). Children with DMII should be screened for CAD, as early diagnosis allows for 
more diverse treatment options (Upchurch, 2012).  
 Hyperlipidemia. Hyperlipidemia is excess lipids, or fats, in the bloodstream, 
including cholesterol and triglycerides. Triglycerides are the most abundant type of fat in 
the body. According to the American Heart Association, healthy triglyceride levels 
should be below 150mg/dl. Forty percent of individuals with DMII have triglyceride 
levels greater than 200mg/dl (“What Your Cholesterol Levels Mean”, 2015). The most 
common dyslipidemic pattern in DMII, diabetic hyperlipidemia, is characterized by 
elevation in triglycerides, low HDL cholesterol, and an increase in small dense LDL 
particles. This particular lipid disturbance pattern is associated with insulin resistance in 
DMII. The insulin resistance is related to the impaired pancreatic and beta cell signaling, 
which leads to decreased insulin sensitivity and excess free glucose in the blood stream. 
An elevation in small dense LDL particles can be detrimental in the presence of pre-
existing cardiac disease. The small LDL particles contribute to atherosclerosis, as they 
are highly susceptible to oxidative modification and increased buildup along the arterial 
wall. Once triglyceride levels reach 132 mg/dl or higher, small LDL particles begin to 
accumulate along arterial walls. This diabetic hyperlipidemia contributes to and 
exacerbates hypertension (Solano & Goldberg, 2006). Children who are diagnosed with 
DMII must have their HDL, triglycerides, and small LDL particles monitored to prevent 
exacerbation of cardiac complications.  
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 Diabetic Cardiomyopathy. Diabetic cardiomyopathy is cardiac disease that is 
characteristically independent of other vascular complications during diabetes. While 
comorbid cardiac conditions may exist, they are not the cause of the diabetic 
cardiomyopathy. The number of cases of diabetic cardiomyopathy each year is growing 
parallel to the number of cases of DMII. Diabetic cardiomyopathy is essentially a heart 
failure syndrome that is characterized by hypertrophy of the left ventricle and decreased 
diastolic function, with or without concurrent systolic dysfunction. Decreased diastolic 
function results in prolonged diastolic relaxation with each heartbeat. This dysfunction 
frequently leads to subsequent progressive fibrosis and impaired serum calcium 
utilization. Cardiac fibrosis and imbalanced serum calcium result in contractility 
dysfunction, cardiac autonomic neuropathy, and excess stress on the heart muscle 
(Mandavia et al., 2013). Typically, diabetic cardiomyopathy is diagnosed in the absence 
of hypertension or CAD. If both hypertension and CAD are present, the diagnosis will be 
congestive heart failure (CHF) rather than diabetic cardiomyopathy. This is because 
diabetic cardiomyopathy, by definition, is heart failure that is not caused by underlying 
cardiac conditions (Isfort, Stevens, Schaffer, Jong, & Wold, 2013). Diabetic 
cardiomyopathy is a progressive disease. Screening for diabetic cardiomyopathy is an 
important component of the management of DMII in children. Because diabetic 
cardiomyopathy does not have underlying cardiac causes, such as hypertensions or CAD, 
it is sometimes unnoticed until the disease has progressed to the point of physiological 
impairment.  
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Renal Failure 
Diabetic nephropathy, a condition caused by poor blood flow to the kidneys, is 
the leading cause of chronic kidney disease (CKD) and end stage renal disease (ESRD) in 
the US (Porth, 2009). Physiologically, diabetic nephropathy causes several dysfunctions 
in the renal system. Dr. Thinzar Min and associates (2012) examined two cross-sectional 
studies to determine the prevalence of diabetic nephropathy in patients with DMII. The 
analysis concludes that, on average, 26% of DMII patients are also diagnosed with 
diabetic nephropathy. These dysfunctions include glomerulosclerosis, chronic vascular 
damage, and increased susceptibility to glomerular diseases related to the 
glomerulosclerosis. Diabetic nephropathy can be diagnosed using several different 
factors. The earliest biochemical marker of diabetic nephropathy is the presence of 
albuminuria, which is excessive albumin protein in the urine. The rate of renal decline is 
directly related to the severity of the albuminuria. Albuminuria is the most sensitive 
indication of CKD. Microalbuminuria is defined as urine albumin levels that are above 
normal, but below the level detectable by dipstick testing. For most patients, 
microalbuminuria marks the beginning of renal impairment, though no outward 
physiological changes may have yet occurred. If microalbuminuria persists, over time it 
will progress to macroalbuminuria. On average, 20% of DMII patients will progress to 
macroalbuminuria levels within five years. Albuminuria causes deterioration in renal 
function. Studies suggest that albumin that would normally be filtered out by the 
glomerulus causes injury to the tubular cells, which leads to tubular fibrosis, or stiffening. 
The etiology, or cause, of diabetic nephropathy is primarily hyperglycemia. Because high 
blood glucose levels and insulin resistance characterize DMII, the renal tissues are 
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overexposed to hyperglycemia. The mesangial cells, which are the cells that make up the 
capillaries within the renal system, are exceptionally sensitive to hyperglycemia. The 
mesangial cells are damaged by hyperglycemia, which impairs their ability to filter 
properly. Thus, albumin builds up in the urine leading to albuminuria (Min, Stephens, 
Kumar, & Chudleigh, 2012). While not all individuals with DMII will develop diabetic 
nephropathy, it is a debilitating complication of DMII. Children who are diagnosed with 
DMII should undergo screening for microalbuminuria to promote early detection of the 
disease.  
Vision Impairment 
Vision impairment due to diabetic retinopathy is a complication of diabetes. 
Retinopathy is a result of microvascular damage to the retina as a result of chronic 
hyperglycemia and hypertension (Carroll, Scott, & Curtis, 2009). In the US, diabetic 
retinopathy is the leading cause of preventable blindness in working-age adults. It is 
estimated that 40% of people with DMII have retinopathy, with eight percent 
experiencing blindness as a result of the disease process. Historically, retinopathy has a 
more significant and debilitating effect on individuals with DMI than those with DMII. 
Research indicates that this is due to the historically later onset of DMII rather than the 
physiological processes of the different types of diabetes. Children who are diagnosed 
with DMII prior to puberty have a 30% greater chance of developing diabetic retinopathy 
than those who are diagnosed after puberty. The physiological changes of puberty, 
including hormones, insulin sensitivity alterations, and adipose redistribution, trigger 
retinopathy. The primary cause of retinopathy is chronic exposure to hyperglycemia. As 
with the renal capillaries, retinal vessels tend to be more sensitive to the toxic effects of 
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chronic hyperglycemia. Hyperglycemia, as well as chronic hypertension, initiates a 
cascade of physiological changes that result in microvascular damage and retinal 
impairment. Several biochemical factors are involved in the cascade, including 
accumulation of sorbitol, oxidative stress resulting in tissue damage, protein kinase C 
activation, and dysfunction of the RAAS. Inflammation is also a key component in the 
destruction of retinal vessels and the development of retinopathy (Cheung, Mitchell, & 
Wong, 2010). The ADA recommends that children who are diagnosed with DMII prior to 
puberty undergo screening for retinopathy within three years of diagnosis. For children 
diagnosed after puberty, screening should take place with annual ophthalmologist visits 
(“Diabetic Retinopathy”, 2007).   
Conclusion 
Over the last three decades, the number of children diagnosed with DMII has 
greatly increased. This rapid increase in childhood DMII has prompted numerous studies 
and extensive research to investigate why the epidemic exists and what its life-long 
ramifications may be for children. Since DMII is a heterogeneous disease with both 
genetic and environmental risk facts, it is imperative that the environmental, or 
modifiable, risk factors before addressed. These include obesity, exercise, diet, and 
breastfeeding in infancy. Due to the chronic nature of DMII, children with the disorder 
are at significant risk for developing additional medical conditions, or co-morbidities. 
These include cardiac complications, renal failure, and vision impairment. Due to the 
early onset of childhood DMII, these co-morbidities are often pronounced and 
debilitating once the child has reached middle adulthood. Childhood DMII is an 
CHILDHOOD TYPE II DIABETES  27 
epidemic. Aggressive effort including the screening for and understanding of the disease 
is imperative to reduce the risks and complications associated with childhood DMII.  
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